Abstract
The purpose of this study is to evaluate the effectiveness and safety of mycophenolate mofetil (MMF) for inducing and/or maintaining remission of lupus nephritis (LN). This is a retrospective study of 25 LN patients consecutively treated with MMF. The primary outcome was complete renal remission (CR) defined by urine protein/creatinine ratio ≤0.5 g/g and inactive urine sediment and serum creatinine within <15% above baseline. For induction, 21 episodes of active, moderate to severe LN were treated with MMF. Twelve cases (57%) achieved CR over a median of 8.5 months. Of 13 patients who had LN for <12 months and took ≥2 g/day of MMF, 11 achieved CR, compared to one out of the eight patients who did not meet both criteria (p = 0.0022). For maintenance therapy, 15 patients received MMF for a median of 20 months (range 5–55 months). Two patients (13%) experienced renal flares while taking MMF. Most adverse events were transient and did not require change in therapy. This study suggests that MMF is an effective treatment for both induction and maintenance of remission of moderate to severe LN with a relatively favorable safety profile. Early treatment and a dose ≥2 g/day are essential for optimal outcome. CR may take >6 months.
Similar content being viewed by others
References
Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC (2004) Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 43:197–208
Moore RA, Derry S (2006) Systematic review and meta-analysis of randomized trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 8:R182
Contreras G, Pardo V, Leclercq B et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725
Dooley MA, Aranow C, Ginzler EM (2004) Review of ACR renal criteria in systemic lupus erythematosus. Lupus 13(11):857–860
Contreras G, Lenz O, Pardo V et al (2006) Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 69:1846
Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162
Chan TM, Tse KC, Tang CSO, Mok MY, Li FK (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076–1084
Disclosures
Partial support for this study was provided by a research grant from Aspreva Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Elyan, M., Ballou, S. The effectiveness and safety of mycophenolate mofetil in lupus nephritis. Clin Rheumatol 28, 835–840 (2009). https://doi.org/10.1007/s10067-009-1163-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-009-1163-6